Literature DB >> 20353988

Obstetric antiphospholipid syndrome: still a challenge.

R A Levy1, G R R Jesús, N R Jesús.   

Abstract

Obstetric complications such as fetal death, premature delivery, preeclampsia and recurrent abortions (since chromosomal or anatomic defects have been excluded) are characteristic manifestations of antiphospholipid syndrome (APS). They can occur in patients with known APS with previous arterial or venous events in any tissue or organ, or be its first and only manifestation. Pregnancy in a patient with APS is considered high risk and the full prenatal clinical follow-up must be carried with this in mind, eliminating or minimizing concomitant thrombotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353988     DOI: 10.1177/0961203309361484

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 2.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 3.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 4.  Managing pregnancy in inflammatory rheumatological diseases.

Authors:  Varsha Jain; Caroline Gordon
Journal:  Arthritis Res Ther       Date:  2011-02-25       Impact factor: 5.156

5.  Study on antiphospholipid/anticardioliplin antibodies in women with recurrent abortion.

Authors:  Farideh Akhlaghi; Mohamad Reza Keramati; Mehri Tafazoli
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.